These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 27832143)

  • 41. Factors associated with efficacy of pegylated interferon-α plus ribavirin for chronic hepatitis C after renal transplantation.
    Li LF; Shi KQ; Lin YQ; Wang LR; He JP; Braddock M; Chen YP; Zheng MH
    Gene; 2014 Jul; 544(2):101-6. PubMed ID: 24793583
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial.
    Berg T; Kronenberger B; Hinrichsen H; Gerlach T; Buggisch P; Herrmann E; Spengler U; Goeser T; Nasser S; Wursthorn K; Pape GR; Hopf U; Zeuzem S
    Hepatology; 2003 Jun; 37(6):1359-67. PubMed ID: 12774015
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vitamin D status and viral response to therapy in hepatitis C infected children.
    Eltayeb AA; Abdou MA; Abdel-aal AM; Othman MH
    World J Gastroenterol; 2015 Jan; 21(4):1284-91. PubMed ID: 25632203
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin.
    Oze T; Hiramatsu N; Yakushijin T; Kurokawa M; Igura T; Mochizuki K; Imanaka K; Yamada A; Oshita M; Hagiwara H; Mita E; Ito T; Inui Y; Hijioka T; Tamura S; Yoshihara H; Hayashi E; Inoue A; Imai Y; Kato M; Yoshida Y; Tatsumi T; Ohkawa K; Kiso S; Kanto T; Kasahara A; Takehara T; Hayashi N
    J Viral Hepat; 2009 Aug; 16(8):578-85. PubMed ID: 19552663
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response.
    Carlsson T; Reichard O; Norkrans G; Bläckberg J; Sangfelt P; Wallmark E; Weiland O
    J Viral Hepat; 2005 Sep; 12(5):473-80. PubMed ID: 16108761
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients.
    Taliani G; Gemignani G; Ferrari C; Aceti A; Bartolozzi D; Blanc PL; Capanni M; Esperti F; Forte P; Guadagnino V; Mari T; Marino N; Milani S; Pasquazzi C; Rosina F; Tacconi D; Toti M; Zignego AL; Messerini L; Stroffolini T;
    Gastroenterology; 2006 Apr; 130(4):1098-106. PubMed ID: 16618404
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C.
    Di Bisceglie AM; Ghalib RH; Hamzeh FM; Rustgi VK
    J Viral Hepat; 2007 Oct; 14(10):721-9. PubMed ID: 17875007
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Associations between human TRIM22 gene expression and the response to combination therapy with Peg-IFNα-2a and ribavirin in Iranian patients with chronic hepatitis C.
    Sadeghi F; Bokharaei-Salim F; Salehi-Vaziri M; Monavari SH; Alavian SM; Salimi S; Vahabpour R; Keyvani H
    J Med Virol; 2014 Sep; 86(9):1499-506. PubMed ID: 24889558
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Metabolic syndrome is associated with poor treatment response to antiviral therapy in chronic hepatitis C genotype 3 patients.
    Aziz H; Gill U; Raza A; Gill ML
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):538-43. PubMed ID: 24642690
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients.
    Reddy KR; Messinger D; Popescu M; Hadziyannis SJ
    J Viral Hepat; 2009 Oct; 16(10):724-31. PubMed ID: 19486469
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An early viral response to standard interferon-alpha identifies resistance to combination therapy with peginterferon and ribavirin in patients infected by HCV genotype 1.
    Toyoda H; Kumada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Tada T; Takagi M; Hiramatsu T; Hosokawa T; Arakawa T; Fujimori M
    J Med Virol; 2010 Sep; 82(9):1537-44. PubMed ID: 20648607
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
    Bernabucci V; Ciancio A; Petta S; Karampatou A; Turco L; Strona S; Critelli R; Todesca P; Cerami C; Sagnelli C; Rizzetto M; Cammà C; Villa E
    World J Gastroenterol; 2014 Nov; 20(44):16726-33. PubMed ID: 25469044
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
    Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
    JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C.
    Conjeevaram HS; Wahed AS; Afdhal N; Howell CD; Everhart JE; Hoofnagle JH;
    Gastroenterology; 2011 Feb; 140(2):469-77. PubMed ID: 21070775
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interplay between vitamin D status and antiviral therapy among chronic hepatitis C Egyptian patients.
    Abd Elalim MH; Zaky DZ; Motawae IA; Mohamed NA; Nagib AN
    J Egypt Soc Parasitol; 2015 Apr; 45(1):17-22. PubMed ID: 26012214
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vitamin D deficiency in hepatitis C virus infection: what is old? what is new?
    Jin CN; Chen JD; Sheng JF
    Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):741-746. PubMed ID: 29664746
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Classical and emerging roles of vitamin D in hepatitis C virus infection.
    Gutierrez JA; Parikh N; Branch AD
    Semin Liver Dis; 2011 Nov; 31(4):387-98. PubMed ID: 22189978
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vitamin D deficiency and HCV chronic infection: what comes first?
    Bitetto D; Fabris C; Falleti E; Toniutto P
    J Hepatol; 2011 Oct; 55(4):944-5; author reply 945. PubMed ID: 21349298
    [No Abstract]   [Full Text] [Related]  

  • 60. Serum level of interleukin-4 is a possible marker of therapeutic response to interferon treatment in patients with chronic hepatitis C.
    Higashi N; Nakamuta M; Motomura K; Enjoji M; Sakai H; Nawata H
    J Hepatol; 1999 Aug; 31(2):383. PubMed ID: 10453958
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.